文献速递妇科

孕激素受体调节剂对子宫内膜的影响具有可逆性

The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
PubMed 文献 · Fertil Steril · 2021-04-14

该横断面研究纳入16例异常子宫出血患者,接受醋酸乌利普司特(UPA)5 mg每日一次、三个12周疗程(间隔4周停药),在治疗前、中、后三个时间点取子宫内膜活检。结果显示UPA改变甾体受体、代谢酶、细胞增殖及孕激素调节基因表达,停药后mRNA水平和内膜形态恢复至治疗前表型。

要点

  • UPA治疗使甾体受体mRNA水平较治疗前分泌期内膜升高。
  • UPA降低17-和11-β-羟甾体脱氢酶mRNA水平并减少细胞增殖。
  • 停药后mRNA水平及内膜形态恢复至治疗前表型,提示可逆。

核心结论

  • 孕激素受体调节剂UPA对子宫内膜的影响在停药后可逆。

研究设计与样本

  • 横断面研究,纳入16例子宫结构正常或影像学发现肌瘤、腺肌症或两者兼有的月经过多患者。
  • 参与者接受UPA 5 mg每日一次,共三个12周疗程,每疗程间隔4周无治疗。
  • 在治疗前、治疗中及停药后三个时间点取子宫内膜活检进行分析。

主要发现

  • UPA治疗使甾体受体mRNA水平较治疗前分泌期内膜升高。
  • UPA使17-和11-β-羟甾体脱氢酶mRNA水平较治疗前增殖期和分泌期内膜降低。
  • UPA使细胞增殖较治疗前增殖期内膜减少,并改变孕激素调节基因的mRNA水平。
  • 免疫组化-数字图像分析与实时定量RT-PCR结果高度一致。
  • 停药后mRNA水平及子宫内膜形态恢复至治疗前表型。

临床怎么用

  • UPA对子宫内膜的分子和形态学改变在停药后恢复,支持其短期使用的可逆性。

局限性

  • 样本量较小(16例),为横断面设计。
  • 研究对象包含子宫结构正常及异常者,异质性可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the impact of the progesterone receptor modulator (PRM), ulipristal acetate (UPA), on endometrial morphology and function. DESIGN: Cross-sectional. SETTING: University Research Institute. PATIENT(S): Endometrial biopsies from 16 patients with heavy menstrual bleeding with a structurally normal uterus or in association with structural abnormalities identified on radiological imaging (fibroids, adenomyosis or a combination of fibroids and adenomyosis). INTERVENTION(S): Participants received UPA (5 mg once daily) for three 12-week courses, each separated by 4 weeks without treatment. MAIN OUTCOME MEASURE(S): Gene expression by real-time quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and digital image analysis were analyzed to investigate the endometrial impact of modulation of progesterone receptor pathways upon expression of steroid receptors, steroid metabolizing enzymes, cell proliferation, and progesterone-regulated genes in the same patients at 3 time points: before, during, and after discontinuation of PRM treatment. RESULT(S): Ulipristal acetate treatment resulted in increased messenger ribonucleic acid (mRNA) levels of steroid receptors compared with pretreatment secretory endometrium; decreased mRNA levels of 17- and 11-beta-hydroxysteroid dehydrogenases compared with pretreatment proliferative endometrium and pretreatment secretory endometrium; reduced cell proliferation compared with pretreatment proliferative endometrium; and altered mRNA levels of progesterone-regulated genes. A strong consistency between immunohistochemistry-digital image analysis and real-time quantitative reverse transcription polymerase chain reaction results was evident. Alterations in the mRNA levels and endometrial morphology returned to a pretreatment phenotype after the cessation of PRM exposure. CONCLUSION(S): The endometrial impact of the modulation of progesterone receptor pathways with PRM (UPA) treatment is reversible. CLINICAL TRIAL REGISTRATION NUMBER: Ulipristal acetate versus conventional management of heavy menstrual bleeding (UCON) trial (EudraCT 2014-003408-65; REC14/LO/1602).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Chodankar RR, Murray A, Nicol M, et al. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible. Fertil Steril. 2021. PMID: 33865567. doi:10.1016/j.fertnstert.2021.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。